TG THERAPEUTICS, INC.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company maintains its corporate website at www.tgtherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TG THERAPEUTICS, INC. does
In the company’s own words
TG Therapeutics, Inc. (NASDAQ: TGTX) is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company maintains its corporate website at www.tgtherapeutics.com.
The company's flagship product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved by the FDA in December 2022 for treating adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. BRIUMVI can be administered via one-hour intravenous infusion every 24 weeks following an initial dosing schedule. The company commercially launched BRIUMVI in the United States in January 2023 and has expanded its availability internationally through a commercialization partnership with Neuraxpharm, a European specialty pharmaceutical company focused on central nervous system disorders. BRIUMVI became available in the European market in February 2024 and is now commercially available in several countries outside the United States.
Beyond its approved product, TG Therapeutics maintains an active pipeline addressing B-cell mediated diseases. The company is evaluating subcutaneous formulations of ublituximab through Phase 3 clinical trials, with enrollment exceeding 75 percent as of February 2026. Additionally, the company is developing simplified dosing schedules for intravenous BRIUMVI and exploring azer-cel, an allogeneic CD19-directed CAR T cell therapy, for progressive forms of multiple sclerosis through Phase 1 trials initiated in August 2025.
The company's business model centers on identifying validated targets in B-cell mediated diseases and acquiring best-in-class compounds with complementary mechanisms. TG Therapeutics licenses its products through strategic partnerships, including exclusive worldwide development and commercial rights for ublituximab from LFB Biotechnologies and GTC Biotherapeutics. The company maintains a patient-focused culture while building its commercial infrastructure to support BRIUMVI's market penetration and pipeline advancement. TG Therapeutics operates as an accelerated filer with the SEC and maintains a well-known seasoned issuer status.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1001316
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TG THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TG THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TG THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TG THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TG THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”